Physician profile
Anna Read
NPI 1376314229
$1,359.00
in general payments reported to CMS, 2019-2025
20 companies · $661 in 2025
The $661 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $698 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,347 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.44 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $358.60 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $293.71 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $126.52 | 2024-2025 | |
| Novo Nordisk INC | $121.60 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $90.86 | 2024 | |
| Gilead Sciences, INC. | $70.35 | 2024 | |
| Lilly USA, LLC | $64.69 | 2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $28.21 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $20.58 | 2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.88 | 2025 | Caplyta |
| Aimmune Therapeutics, INC. | $19.61 | 2025 | Zenpep |
| Lexicon Pharmaceuticals, INC. | $17.60 | 2024 | |
| Lundbeck LLC | $17.45 | 2025 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $17.27 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $17.06 | 2025 | Austedo Xr |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.92 | 2024 | Xarelto |
| Mylan Specialty L.P. | $15.56 | 2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $15.32 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.70 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $13.51 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Read listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.